Retreatment of Lung Adenocarcinoma Patients With Gefitinib Who Had Experienced Favorable Results From Their Initial Treatment With This Selective Epidermal Growth Factor Receptor Inhibitor: A Report of Three Cases

Seiji Yano(Kanazawa University), Saburo Sone(Io Therapeutics (United States)), Naoki Nishikubo(Tokushima University), Mami Inayama(Tokushima University), Nobutaka Edakuni(Tokushima University), Emiko Nakataki(Tokushima University), S. Ohtsuka(Tokushima University), Soji Kakiuchi(Tokushima Prefectural Central Hospital), Hideki Tomimoto(Tokushima University), Hiroaki Muguruma(Tokushima University)
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
February 1, 2005
10.3727/096504005775082020
Cited by 97

Related Papers

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
|Cancer Research|2008|642
Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs
|Oncogene|2003|324
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
|Human Molecular Genetics|2004|175
The Neuromedin U-Growth Hormone Secretagogue Receptor 1b/Neurotensin Receptor 1 Oncogenic Signaling Pathway as a Therapeutic Target for Lung Cancer
|Cancer Research|2006|134
Plakophilin 3 Oncogene as Prognostic Marker and Therapeutic Target for Lung Cancer
|Cancer Research|2005|124